1. Home
  2. KNSA vs NWBI Comparison

KNSA vs NWBI Comparison

Compare KNSA & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • NWBI
  • Stock Information
  • Founded
  • KNSA 2015
  • NWBI 1896
  • Country
  • KNSA United Kingdom
  • NWBI United States
  • Employees
  • KNSA N/A
  • NWBI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • NWBI Major Banks
  • Sector
  • KNSA Health Care
  • NWBI Finance
  • Exchange
  • KNSA Nasdaq
  • NWBI Nasdaq
  • Market Cap
  • KNSA 1.4B
  • NWBI 1.6B
  • IPO Year
  • KNSA 2018
  • NWBI N/A
  • Fundamental
  • Price
  • KNSA $20.02
  • NWBI $12.57
  • Analyst Decision
  • KNSA Strong Buy
  • NWBI Sell
  • Analyst Count
  • KNSA 5
  • NWBI 2
  • Target Price
  • KNSA $36.60
  • NWBI $12.50
  • AVG Volume (30 Days)
  • KNSA 567.6K
  • NWBI 703.2K
  • Earning Date
  • KNSA 02-25-2025
  • NWBI 01-24-2025
  • Dividend Yield
  • KNSA N/A
  • NWBI 6.36%
  • EPS Growth
  • KNSA N/A
  • NWBI N/A
  • EPS
  • KNSA N/A
  • NWBI 0.79
  • Revenue
  • KNSA $384,098,000.00
  • NWBI $498,083,000.00
  • Revenue This Year
  • KNSA $60.10
  • NWBI N/A
  • Revenue Next Year
  • KNSA $34.22
  • NWBI $16.29
  • P/E Ratio
  • KNSA N/A
  • NWBI $15.91
  • Revenue Growth
  • KNSA 54.41
  • NWBI N/A
  • 52 Week Low
  • KNSA $16.56
  • NWBI $10.45
  • 52 Week High
  • KNSA $28.15
  • NWBI $15.42
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 53.15
  • NWBI 37.66
  • Support Level
  • KNSA $19.31
  • NWBI $12.49
  • Resistance Level
  • KNSA $20.20
  • NWBI $13.25
  • Average True Range (ATR)
  • KNSA 0.80
  • NWBI 0.28
  • MACD
  • KNSA 0.06
  • NWBI -0.04
  • Stochastic Oscillator
  • KNSA 72.80
  • NWBI 8.51

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About NWBI Northwest Bancshares Inc.

Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and banking business solutions, investment management, trust services and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.

Share on Social Networks: